Digestive Health - Finding Better Balance
Posted on Tue, 03 Sep 2019
by Mal Evans, PhD Chief Scientific Officer at KGK Science.
Slow digestion can be uncomfortable, leaving many of us feeling bloated, gassy and fatigued. Not only do irregular bowel habits disrupt our daily routine, but constipation is a symptom reported by approximately 38% of the Canadian population. Looking beyond the old advice for more fluids, fibre and physical activity, some natural health products offer new solutions for our intestinal health by promoting bowel regularity. Exciting research is being completed in London to examine the relationship between intestinal health and bowel regularity.
We are studying a new strategy for the improvement and maintenance of bowel function using two daily supplements, Actazin® and Livaux®. Both are sourced from non-GMO New Zealand whole kiwi fruit and offer several bioactive components that work to gently and effectively improve bowel function.
Improving the composition of the bacterial communities, or the microbiome, within our digestive tract has been the target of research over the past decade. Scientific research has revealed that beneficial gut bacteria have an important influence on our overall health and wellbeing.
Our bodies need the right balance of beneficial bacteria to suppress populations of undesirable bacteria. This proper balance can be disrupted by changes in stress, infrequent use of antibiotics and the wrong types of food.
Diet plays an important role in the composition of the microbiome. Kiwi fruit, in particular, contains many components that contribute to its laxative effect. Actinidin is an enzyme found exclusively in green kiwifruit that enhances digestion of food proteins. Kiwi flesh also contains both soluble and insoluble fibre that retain water in the gut and provides bulk for softer stools. The swelling capacity of kiwi fruit fibre has actually been shown to be 12 times higher than wheat bran, a common fibre supplement found in many cereals and fibre products. Kiwi fibre also acts as a prebiotic to feed the good bacteria that produce beneficial short-chain fatty acids in our gut.
One example of a beneficial bacteria would be F. prau (Faecalibacterium prausnitzii), one of the most abundant bacteria found in our gut, making up approximately 5% of our microbiome. F. prau supplies important molecules taken up for energy by cells lining our large intestine. Thus, appropriate levels of F. prau is necessary to regulate bowel function and reduce gastrointestinal inflammation. Unfortunately, F. prau is not available as a probiotic as it can’t be exposed to the air. The best strategy to look after the F. prau you have is by taking prebiotics such as Actazin® and Livaux® that helps them multiply and thrive.
KGK Science Inc is currently conducting a clinical research study in London lasting 28 days to evaluate the effects of whole kiwi fruit on digestive health. We are interested in examining the effects of these TWO prebiotics and fibre on improvements in bowel regularity in men and women ages 18 to 60.
As a participant, you will have the satisfaction of knowing that you are part of cutting edge nutrition research that will bring scientifically tested novel products to market. We are currently looking for participants who are interested in taking part in this new research. All records relating to your identity and study participation are confidential under the Personal Information Protection and Electronic Documents Act. KGK’s clinical trials are conducted under the direction of a Medical Director and Principal Investigator. All studies are reviewed by an independent ethics review board, follow Good Clinical Practice, and are approved by Health Canada. Each study has its own guidelines for who can participate– eligibility criteria.
To ensure the strongest results, researchers want to study participants to be alike in key ways. Examples of eligibility criteria for a treatment trial might be age, gender, weight, height, and/or your previous medical history. Additional information will be determined upon telephone or online screening. There are no out-of-pocket expenses for you to join this clinical trial. Parking at One London Place will be validated, or bus fare provided, and participants will be compensated up to $600 for their time + $25 to complete an in-clinic screening visit with our doctors.